MedPath

Impact of the analgesic drug dipyrone (metamizole) on the antiplatelet effect of aspirin in patients after cardiac surgyer

Phase 1
Conditions
Antithrombotic therapy after surgical replacement of stenotic heart valve by a bioprosthesis or mitral valve repair
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Registration Number
EUCTR2018-000017-20-DE
Lead Sponsor
niversitäts-Herzzentrum Freiburg • Bad Krozingen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
Not specified
Target Recruitment
150
Inclusion Criteria

-Clinical indication for surgical replacement of the stenotic aortic valve by a bioprosthesis without concomitant CABG or surgical mitral valve repair
-Age > 50years
-Written informed consent

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 15
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 135

Exclusion Criteria

-Re-do heart surgery
-Indication for oral anticoagulation
-Known disorders of coagulation
-Chronic hepatic disease
-Chronic alcohol abuse
-Known malnutrition status
-Creatine clearance <30 ml7Min (CKD-EPI-formula)
-End-stage renal disease requring hemodialysis
-Known hematological disorders
-Peri-or postoperative transfusion of platelets
-Treatment with aspirin within 10 days prior to surgery
-Positive result in pregnancy in urine testing in female pre-menopausal patients
-Participation in any interventional study according to German Drug Law (AMG) or Medicinal Device Law (MPG) within 30 days before enrollment in this study
-Known hypersensitivity to dipyrone (metamizole) or paracetamol

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath